| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
10 May 2024 5:05PM |
$0.004 |
$0.520 |
risen by
12,900%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Notification regarding unquoted securities - OSL
|
8 May 2024 4:39PM |
$0.005 |
$0.520 |
risen by
11,455.56%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
8 May 2024 4:34PM |
$0.005 |
$0.520 |
risen by
11,455.56%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Notification regarding unquoted securities - OSL
|
3 May 2024 5:11PM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
3 May 2024 5:10PM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Notification regarding unquoted securities - OSL
|
2 May 2024 10:57AM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
2 May 2024 10:52AM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
$5.3 million raised under Entitlement Offer
|
2 May 2024 10:48AM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited completed a fully underwritten Entitlement Offer raising $5.3 million.
- The offer was made on a 2-for-5 basis at $0.016 per New Share with free attaching options.
- Funds raised will support clinical development, regulatory programs, commercialization, and working capital.
- Directors and key stakeholders have shown support for the Entitlement Offer.
- The announcement details the structure, timetable, and risk factors associated with the capital raise.
- The funds are intended to strengthen the balance sheet and advance OncoSilâ„¢ for pancreatic cancer.
- The offer is aimed at eligible shareholders with a record date specified in the announcement.
- The company emphasizes its commitment to clinical progress and commercialization strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
1st Study in Man Increases Pancreatic Tumor Vascularity
|
1 May 2024 8:28AM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited announced results from the first-in-human study of the OncoSilâ„¢ device for pancreatic cancer.
- The OncoSilâ„¢ device is a brachytherapy device designed to deliver localized radiation directly to tumors.
- The study demonstrated a significant increase in tumor vascularity following OncoSilâ„¢ treatment.
- Increased tumor vascularity may enhance the delivery and effectiveness of both radiation and systemic therapies.
- The results indicate the OncoSilâ„¢ device is safe and well-tolerated in humans.
- The findings suggest potential improvement in clinical outcomes for patients with inoperable pancreatic cancer.
- The announcement highlights the broader potential of OncoSilâ„¢ for other difficult-to-treat solid tumors.
- The study supports ongoing and future clinical development of the OncoSilâ„¢ device.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2024 3:52PM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- OncoSilâ„¢ device commercial activity advanced in the UK, Germany, Italy, and Australia.
- Expansion into France initiated, with regulatory and market access efforts ongoing.
- PanCO clinical study completed patient recruitment; positive results published.
- New clinical data from UK registry study presented at major conferences.
- Quarterly cash receipts amounted to $632k; R&D expenditure was $1,350k.
- Total cash outflows for the quarter were $3.0 million.
- A successful capital raise of $6.2 million completed to strengthen cash reserves.
- Cash at quarter end was $5.5 million, up from the previous quarter.
- Focus remains on commercial growth, reimbursement approvals, and expanding clinical indications.
- Outlook includes continued international market access and further clinical research.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Two more PANCOSIL Trial treatments using OncoSil device
|
17 Apr 2024 5:07PM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
First patient treated with OncoSil device in Turkiye
|
16 Apr 2024 8:58AM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- OncoSil Medical Limited marked the first commercial treatment with OncoSil device in Türkiye.
- The treated patient had locally advanced pancreatic cancer.
- The procedure took place at a prominent hospital in Türkiye.
- This milestone is part of OncoSil’s expansion into international markets.
- Regulatory approval and clinician training preceded the first treatment.
- The company views this event as a demonstration of growing global demand.
- The OncoSil device is now commercially available in Türkiye.
- Expansion into Türkiye aligns with OncoSil’s global growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Notice of Extraordinary General Meeting/Proxy Form
|
16 Apr 2024 8:47AM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
First patient treated in the UK for the TRIPP-FXX study
|
12 Apr 2024 8:26AM |
$0.006 |
$0.520 |
risen by
8,566.67%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited has commenced patient treatment in the UK as part of the TRIPP-FXX study.
- The first UK patient was treated with the OncoSilâ„¢ device for locally advanced pancreatic cancer.
- The TRIPP-FXX study is a post-marketing clinical investigation focused on efficacy and safety.
- Treatment in the UK marks an expansion of Oncosil Medical’s clinical activity in Europe.
- The OncoSilâ„¢ device is intended for use in patients with locally advanced pancreatic cancer.
- This milestone reinforces the company’s commitment to improving outcomes in pancreatic cancer.
- The announcement underlines progress in Oncosil Medical’s ongoing clinical program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
UK Private Insurer Approves Reimbursement for OncoSil
|
9 Apr 2024 9:34AM |
$0.006 |
$0.520 |
risen by
8,566.67%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
First Austria-based treatments utilising the OncoSil device
|
5 Apr 2024 8:38AM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited completed the first Austria-based treatments using the OncoSil device.
- Treatments occurred at University Hospital Krems.
- OncoSil device is a brachytherapy implant for locally advanced pancreatic cancer.
- Device delivers targeted radiation directly into the tumor.
- This marks the first time the therapy is offered in Austria.
- Milestone expands Oncosil's European presence.
- Provides new therapy options for patients with limited alternatives.
- Company considers the event significant for its international growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Dispatch of Entitlement Offer Prospectus
|
4 Apr 2024 9:35AM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Notice under section 708A
|
28 Mar 2024 4:12PM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
28 Mar 2024 4:02PM |
$0.005 |
$0.520 |
risen by
10,300%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Prospectus - Entitlement Offer
|
25 Mar 2024 8:54AM |
$0.006 |
$0.520 |
risen by
8,566.67%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- OncoSil Medical Limited (OSL) is conducting a non-renounceable entitlement offer to raise approximately $5 million.
- The offer is made to eligible shareholders on a pro-rata basis to fund clinical, regulatory, and operational activities.
- Funds will also be used for working capital and general corporate purposes.
- The OncoSil device is intended for the treatment of pancreatic and other cancers.
- The prospectus contains details on the offer structure, eligibility, risks, and important dates.
- Background on OSL’s business, management team, and financial information is provided.
- The document highlights relevant risks, including regulatory, clinical, market, and financial risks.
- Instructions for participation in the entitlement offer and application procedures are included.
- The offer is not underwritten.
- Ongoing development and commercialization of the OncoSil device is a key strategic focus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Update - Proposed issue of securities - OSL
|
22 Mar 2024 2:50PM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Placement and Entitlement Offer - amended timetable
|
22 Mar 2024 2:32PM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Update - Proposed issue of securities - OSL
|
22 Mar 2024 8:20AM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Placement and Entitlement Offer - addendum
|
21 Mar 2024 9:32AM |
$0.007 |
$0.520 |
risen by
7,328.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Investor Presentation
|
20 Mar 2024 10:28AM |
$0.008 |
$0.520 |
risen by
6,400%
|
|